Multiple Sclerosis is an autoimmune disease that results in progressive deterioration of the central nervous system. There are approximately 300,000-350,000 individuals in the US and 1 million worldwide who are affected with Multiple Sclerosis. Current therapies are mostly anti-inflammatory, targeting early stages of Multiple Sclerosis. Our proprietary technology would allow us to treat broad stage of MS by targeting specific molecules that are associated with risk and progression of multiple sclerosis.

Rheumatoid arthritis is among the most common autoimmune diseases. RA affects 0.5-1% of humans. Biologics have emerged as the leading therapeutics, with a combined market of approximately $12 billion in 2008. Despite the remarkable efficacy, significant portion of RA patients are not responsive to this class of drugs. Therefore, there is an urgent need to develop therapeutic that can complement existing therapeutic biologics. Our technology targets on danger (or damage)-associated molecular patterns (DAMPs) associated pathway, which was recently demonstrated to be a key component in the pathogenesis of RA.

Tuberous Sclerosis is a genetic disease characterized by developing benign tumors in the brain and other vital organs such as kidneys, heart, eyes, lungs, and skin. There are approximately 50,000 individuals and 1 million worldwide, who suffer TSC. There is currently no specific cure for this disease and the treatment is symptomatic. This would render our product as orphan-drug for the treatment of TSC. The efficacy of the patented therapeutic method has been independently verified by several medical centers with publications in the New England Journal of Medicine. Our near term goals are to complete combined phase I/II clinical trial for Tuberous Sclerosis.

Acute Myeloid Leukemia is the most common myeloid leukemia, accounting for more than 25% of leukemia in the US. It is estimated that 12,800 new cases will be reported in 2009 with 9000 death. Post remission therapy of hematological malignancy remains a major challenge, largely due to the development of multi-drug resistance and cancer stem cells as the obstacles for the effective post-remission therapy. Our licensed technology targets on hypoxia-inducible factor, and selectively eliminates AML cancer stem cells and therefore, provides an effective and novel treatment for AML.

Diabetic nephropathy is the leading cause of end-stage renal disease. Approximately 30% of type 1 diabetics and 10% of type 2 diabetics develop diabetic nephropathy. The current drug treatment has very little effect on preventing progression to end-stage renal disease (ESDR) in diabetic patients. Once patients develop ESDR, the only available treatment is kidney dialysis. Therefore, there are approximately 2.3 million patients in the US without effective treatment, resulting in a significant unmet medical need. The technology licensed by OncoImmune has been proven with strong preclinical data generated from animal models.

R&D Operations We operate in our R & D facilities in Ann Arbor, Michigan with active collaborations with the University of Michigan and the Ohio State University.